Abstracts tagged "pulmonary complications"

Abstract Number: 1507 • 2012 ACR/ARHP Annual Meeting
Propylthiouracil Reduces Fibrosis in Chronic Oxidant Stress Mouse Model of Scleroderma
Gianluca Bagnato¹, Alessandra Bitto², Natasha Irrera², Gabriele Pizzino², Neal Roberts³, Maurizio Cinquegrani⁴, Donatella Sangari¹, Francesco Squadrito², Gianfilippo Bagnato¹ and Antonino Saitta⁴, ¹Rheumatology, University of Messina, Messina, Italy, ²Pharmacology, University of Messina, Messina, Italy, ³Medical College of Virginia, Richmond, VA, ⁴Internal Medicine, University of Messina, Messina, Italy
Background/Purpose: Systemic sclerosis (SSc) is characterized by fibrosis of skin and visceral organs; vascular damage and resultant ischemia; and immunological dysregulation manifested by autoantibodies. Hypothyroidism,…
Abstract Number: 1508 • 2012 ACR/ARHP Annual Meeting
Simvastatin Attenuates Pulmonary Fibrosis in a Murine Model of Systemic Sclerosis
Gianluca Bagnato¹, Alessandra Bitto², Natasha Irrera², Gabriele Pizzino², Donatella Sangari¹, Maurizio Cinquegrani³, Neal Roberts⁴, Gianfilippo Bagnato¹, Francesco Squadrito² and Antonino Saitta³, ¹Rheumatology, University of Messina, Messina, Italy, ²Pharmacology, University of Messina, Messina, Italy, ³Internal Medicine, University of Messina, Messina, Italy, ⁴Medical College of Virginia, Richmond, VA
Background/Purpose: Simvastatin is best known for its antilipidemic action due to its inhibition of 3-hydroxy-3-methylglutaryl CoenzymeA (HMG CoA) reductase. Inhibition of biological precursors in this pathway also…
Abstract Number: 720 • 2012 ACR/ARHP Annual Meeting
Left-Heart Disease Is a Frequent Cause of Pulmonary Hypertension in Systemic Sclerosis, Is Associated with Increased Levels of MR-ProANP and MR-ProADM but Is Unrelated to Elevated NT-ProBNP Levels: A Retrospective Cohort Analysis
Lada Miller¹, Sandra Chartrand¹, Martial Koenig², Jean-Richard Goulet³, Eric Rich¹, Michal Abrahamowicz⁴, Jean-Luc Senécal¹ and Tamara Grodzicky¹, ¹Rheumatology, Hôpital Notre-Dame du CHUM, Montreal, QC, Canada, ²Internal Medicine, Hôpital Notre-Dame du CHUM, Montréal, QC, Canada, ³Rheumatology, Hôpital Notre-Dame du CHUM, Montréal, QC, Canada, ⁴Centre Universitaire de Santé McGill (CUSM), Montreal, QC, Canada
Background/Purpose: Pulmonary hypertension (PH) is a significant cause of morbidity and mortality in systemic sclerosis (SSc). Pulmonary arterial hypertension (PAH) is reportedly the most frequent…
Abstract Number: 721 • 2012 ACR/ARHP Annual Meeting
Measurement of Pulmonary Arteries by Cardiac Magnetic Resonance Imaging: A Simple and Useful Tool for the Detection of Pulmonary Hypertension in Systemic Sclerosis Patients without Overt Cardiac Microvascular Perfusion Defects or Fibrosis
Sandra Chartrand¹, Lada Miller¹, Martial Koenig², Jean-Richard Goulet¹, Eric Rich¹, Anne S. Chin³, Yves Provost³, Carl Chartrand-Lefebvre³, Pauline Gou¹, Jean-Luc Senécal¹ and Tamara Grodzicky¹, ¹Rheumatology, Hôpital Notre-Dame du CHUM, Montréal, QC, Canada, ²Internal Medicine, Hôpital Notre-Dame du CHUM, Montréal, QC, Canada, ³Radiology, Hôtel-Dieu de Montréal du CHUM, Montréal, QC, Canada
Background/Purpose: Pulmonary hypertension (PH) is a major complication of systemic sclerosis (SSc). We observed that a significant proportion of our SSc patients with PH as…
Abstract Number: 723 • 2012 ACR/ARHP Annual Meeting
Renal Dysfunction and Disease Severity in Scleroderma-Associated Pulmonary Arterial Hypertension
Stephen C. Mathai¹, Laura K. Hummers² and Virginia D. Steen³, ¹Medicine, Johns Hopkins University, Baltimore, MD, ²Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³Department of Rheumatology, Georgetown University Medical Center, Washington, DC
Background/Purpose: Renal disease is a common complication of scleroderma (SSc). Isolated reduction in glomerular filtration rate (GFR), a marker of impaired renal function, can occur…
Abstract Number: 217 • 2012 ACR/ARHP Annual Meeting
Myositis-Associated Usual Interstitial Pneumonia Has Better Survival Than Idiopathic Pulmonary Fibrosis
Christine McBurney¹, Rohit Aggarwal², Kevin Gibson³, Kathleen Lindell⁴, Carl Fuhrman⁵, Diane Koontz⁶, Frank Schneider⁷, Naftali Kaminski⁴ and Chester V. Oddis⁸, ¹Rheumatology, University of Pittsburgh, Pittsburgh, PA, ²Medicine, University of Pittsburgh, Pittsburgh, PA, ³Division of Pulmonary, Allergy and Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, ⁴University of Pittsburgh Dorothy P. & Richard P. Simmons Center for Lung Disease, Pittsburgh, PA, ⁵Radiology, Division of Thoracic Imaging, University of Pittsburgh, Pittsburgh, PA, ⁶Department of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁷Anatomic Pathology Department, Pittsburgh, PA, ⁸Rheum/Clinical Immunology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Usual interstitial pneumonia associated with idiopathic pulmonary fibrosis (IPF-UIP) has a poor prognosis with a median survival of 3 years. It is unknown whether…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].